Difference between revisions of "HIV-associated lymphoma"
Warner-admin (talk | contribs) |
m |
||
Line 30: | Line 30: | ||
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895225/ Kaplan et al. 2005 (AMC010)] |
|style="background-color:#00CD00"|Phase III | |style="background-color:#00CD00"|Phase III | ||
|[[#R-CHOP|R-CHOP]] | |[[#R-CHOP|R-CHOP]] | ||
Line 44: | Line 44: | ||
====Supportive medications==== | ====Supportive medications==== | ||
*Combination antiretrovirals were required | *Combination antiretrovirals were required | ||
− | *[[Filgrastim (Neupogen)|G-CSF]] 5 mcg/kg SC once per day from days 4 to 13 or until ANC | + | *[[Filgrastim (Neupogen)|G-CSF]] 5 mcg/kg SC once per day from days 4 to 13 or until ANC greater than 10k/uL. |
*Pneumocystis cariini prophylaxis with ONE of the following: | *Pneumocystis cariini prophylaxis with ONE of the following: | ||
**[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Cotrimoxazole]] (dose/route/schedule not specified) | **[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Cotrimoxazole]] (dose/route/schedule not specified) | ||
Line 56: | Line 56: | ||
===References=== | ===References=== | ||
− | # Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, Levine AM, Scadden DT. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005 Sep 1;106(5):1538-43. Epub 2005 May 24. [http://bloodjournal.hematologylibrary.org/content/106/5/1538.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15914552 PubMed] | + | # Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, Levine AM, Scadden DT. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005 Sep 1;106(5):1538-43. Epub 2005 May 24. [http://bloodjournal.hematologylibrary.org/content/106/5/1538.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895225/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/15914552 PubMed] |
==CODOX-M/IVAC {{#subobject:4b6b9|Regimen=1}}== | ==CODOX-M/IVAC {{#subobject:4b6b9|Regimen=1}}== | ||
Line 83: | Line 83: | ||
*Patients are stratified into high and low risk: | *Patients are stratified into high and low risk: | ||
**Low risk patients must fulfill all of the following criteria: | **Low risk patients must fulfill all of the following criteria: | ||
− | ***Serum LDH within the institution's normal range (for the NCI, this was | + | ***Serum LDH within the institution's normal range (for the NCI, this was less than 350 IU/L) |
***Single extraabdominal mass or completely resected abdominal disease | ***Single extraabdominal mass or completely resected abdominal disease | ||
**Any patients which do not meet low risk criteria are classified as high risk | **Any patients which do not meet low risk criteria are classified as high risk | ||
Line 106: | Line 106: | ||
====Supportive medications==== | ====Supportive medications==== | ||
− | *[[Folinic acid (Leucovorin)]] 192 mg/m<sup>2</sup> IV once on day 11, starting 36 hours after the start of the day 10 [[Methotrexate (MTX)]], then 12 mg/m<sup>2</sup> IV every 6 hours thereafter until serum methotrexate level is | + | *[[Folinic acid (Leucovorin)]] 192 mg/m<sup>2</sup> IV once on day 11, starting 36 hours after the start of the day 10 [[Methotrexate (MTX)]], then 12 mg/m<sup>2</sup> IV every 6 hours thereafter until serum methotrexate level is less than 50 nmol/L |
− | *[[Sargramostim (Leukine)|GM-CSF]] 7.5 mcg/kg SC once per day, starting on day 13 and continuing until ANC | + | *[[Sargramostim (Leukine)|GM-CSF]] 7.5 mcg/kg SC once per day, starting on day 13 and continuing until ANC greater than 1000/uL |
====Part A: CODOX-M for low risk patients==== | ====Part A: CODOX-M for low risk patients==== | ||
Line 122: | Line 122: | ||
====Supportive medications==== | ====Supportive medications==== | ||
− | *[[Folinic acid (Leucovorin)]] 192 mg/m<sup>2</sup> IV once on day 11, starting 36 hours after the start of the day 10 [[Methotrexate (MTX)]], then 12 mg/m<sup>2</sup> IV every 6 hours thereafter until serum methotrexate level is | + | *[[Folinic acid (Leucovorin)]] 192 mg/m<sup>2</sup> IV once on day 11, starting 36 hours after the start of the day 10 [[Methotrexate (MTX)]], then 12 mg/m<sup>2</sup> IV every 6 hours thereafter until serum methotrexate level is less than 50 nmol/L |
*No [[Sargramostim (Leukine)|GM-CSF]] used for low risk patients | *No [[Sargramostim (Leukine)|GM-CSF]] used for low risk patients | ||
Line 139: | Line 139: | ||
====Supportive medications==== | ====Supportive medications==== | ||
*[[Mesna (Mesnex)]] 360 mg/m<sup>2</sup> IV every 3 hours on days 1 to 5, given at same time as [[Ifosfamide (Ifex)]] | *[[Mesna (Mesnex)]] 360 mg/m<sup>2</sup> IV every 3 hours on days 1 to 5, given at same time as [[Ifosfamide (Ifex)]] | ||
− | *[[Sargramostim (Leukine)|GM-CSF]] 7.5 mcg/kg SC once per day, starting on day 7 and continuing until ANC | + | *[[Sargramostim (Leukine)|GM-CSF]] 7.5 mcg/kg SC once per day, starting on day 7 and continuing until ANC greater than 1000/uL |
− | '''High risk patients receive Part A: CODOX-M and Part B: IVAC given in an alternating fashion x total of 4 cycles (A, B, A, B)'''. '''Low risk patients receive Part A: CODOX-M x 3 cycles only.''' Each cycle starts on the same day that the patient's ANC is | + | '''High risk patients receive Part A: CODOX-M and Part B: IVAC given in an alternating fashion x total of 4 cycles (A, B, A, B)'''. '''Low risk patients receive Part A: CODOX-M x 3 cycles only.''' Each cycle starts on the same day that the patient's ANC is greater than 1000/uL. |
===References=== | ===References=== | ||
Line 160: | Line 160: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2532802/ Mead et al. 2008 (MRC/NCRI LY10)] |
|style="background-color:#EEEE00"|Non-randomized | |style="background-color:#EEEE00"|Non-randomized | ||
|- | |- | ||
Line 191: | Line 191: | ||
====Supportive medications==== | ====Supportive medications==== | ||
− | *[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> IV every 3 hours x 5 doses on day 11, starting 36 hours after start of the day 10 [[Methotrexate (MTX)]], then 15 mg/m<sup>2</sup> IV every 6 hours until methotrexate level is | + | *[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> IV every 3 hours x 5 doses on day 11, starting 36 hours after start of the day 10 [[Methotrexate (MTX)]], then 15 mg/m<sup>2</sup> IV every 6 hours until methotrexate level is less than 50 nmol/L |
*[[Folinic acid (Leucovorin)]] 15 mg PO once on day 16, 24 hours after intrathecal [[Methotrexate (MTX)]] | *[[Folinic acid (Leucovorin)]] 15 mg PO once on day 16, 24 hours after intrathecal [[Methotrexate (MTX)]] | ||
− | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting on day 13 and continuing until ANC | + | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting on day 13 and continuing until ANC greater than 1000/uL |
*[[Allopurinol (Zyloprim)]] PO and/or [[Rasburicase (Elitek)]] prior to starting chemotherapy | *[[Allopurinol (Zyloprim)]] PO and/or [[Rasburicase (Elitek)]] prior to starting chemotherapy | ||
Line 213: | Line 213: | ||
**Patients older than 65 years old: 200 mg/m<sup>2</sup> (mixed with [[Ifosfamide (Ifex)]]) IV over 1 hour on days 1 to 5, then 200 mg/m<sup>2</sup> IV every four hours x 2 doses on days 1 to 5 | **Patients older than 65 years old: 200 mg/m<sup>2</sup> (mixed with [[Ifosfamide (Ifex)]]) IV over 1 hour on days 1 to 5, then 200 mg/m<sup>2</sup> IV every four hours x 2 doses on days 1 to 5 | ||
*[[Folinic acid (Leucovorin)]] 15 mg PO once on day 6, 24 hours after intrathecal [[Methotrexate (MTX)]] | *[[Folinic acid (Leucovorin)]] 15 mg PO once on day 6, 24 hours after intrathecal [[Methotrexate (MTX)]] | ||
− | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting on day 7 and continuing until ANC | + | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting on day 7 and continuing until ANC greater than 1000/uL |
− | '''High risk patients receive Part A: dmCODOX-M and Part B: IVAC given in an alternating fashion x total of 4 cycles (A, B, A, B)'''. '''Low risk patients receive Part A: dmCODOX-M x 3 cycles only.''' Each cycle starts on the same day that the patient's ANC is | + | '''High risk patients receive Part A: dmCODOX-M and Part B: IVAC given in an alternating fashion x total of 4 cycles (A, B, A, B)'''. '''Low risk patients receive Part A: dmCODOX-M x 3 cycles only.''' Each cycle starts on the same day that the patient's ANC is greater than 1000/uL and unsupported (that is, without transfusion) platelet count greater than 75 x 10<sup>9</sup>/L |
===References=== | ===References=== | ||
− | # Mead GM, Barrans SL, Qian W, Walewski J, Radford JA, Wolf M, Clawson SM, Stenning SP, Yule CL, Jack AS; UK National Cancer Research Institute Lymphoma Clinical Studies Group; Australasian Leukaemia and Lymphoma Group. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008 Sep 15;112(6):2248-60. Epub 2008 Jul 8. [http://bloodjournal.hematologylibrary.org/content/112/6/2248.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18612102 PubMed] | + | # Mead GM, Barrans SL, Qian W, Walewski J, Radford JA, Wolf M, Clawson SM, Stenning SP, Yule CL, Jack AS; UK National Cancer Research Institute Lymphoma Clinical Studies Group; Australasian Leukaemia and Lymphoma Group. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008 Sep 15;112(6):2248-60. Epub 2008 Jul 8. [http://bloodjournal.hematologylibrary.org/content/112/6/2248.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2532802/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18612102 PubMed] |
==DR-COP {{#subobject:ec091e|Regimen=1}}== | ==DR-COP {{#subobject:ec091e|Regimen=1}}== | ||
Line 232: | Line 232: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3530691/ Levine et al. 2012 (AMC047)] |
|style="background-color:#EEEE00"|Phase II | |style="background-color:#EEEE00"|Phase II | ||
|- | |- | ||
Line 249: | Line 249: | ||
*Erythropoietin (e.g. [[Epoetin alfa (Procrit)]] or [[Darbepoetin alfa (Aranesp)]]) at physician discretion | *Erythropoietin (e.g. [[Epoetin alfa (Procrit)]] or [[Darbepoetin alfa (Aranesp)]]) at physician discretion | ||
*PCP prophylaxis required | *PCP prophylaxis required | ||
− | *Oral quinolone if CD4 cell count | + | *Oral quinolone if CD4 cell count less than or equal to 100 and absolute neutrophil count (ANC) less than 500/uL at entry or during treatment |
'''21 to 28 day cycle for up to 6 cycles''' | '''21 to 28 day cycle for up to 6 cycles''' | ||
===References=== | ===References=== | ||
− | # Levine AM, Noy A, Lee JY, Tam W, Ramos JC, Henry DH, Parekh S, Reid EG, Mitsuyasu R, Cooley T, Dezube BJ, Ratner L, Cesarman E, Tulpule A. Pegylated Liposomal Doxorubicin, Rituximab, Cyclophosphamide, Vincristine, and Prednisone in AIDS-Related Lymphoma: AIDS Malignancy Consortium Study 047. J Clin Oncol. 2013 Jan 1;31(1):58-64. Epub 2012 Nov 19. [http://jco.ascopubs.org/content/31/1/58.full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3530691/ link to PMC article] | + | # Levine AM, Noy A, Lee JY, Tam W, Ramos JC, Henry DH, Parekh S, Reid EG, Mitsuyasu R, Cooley T, Dezube BJ, Ratner L, Cesarman E, Tulpule A. Pegylated Liposomal Doxorubicin, Rituximab, Cyclophosphamide, Vincristine, and Prednisone in AIDS-Related Lymphoma: AIDS Malignancy Consortium Study 047. J Clin Oncol. 2013 Jan 1;31(1):58-64. Epub 2012 Nov 19. [http://jco.ascopubs.org/content/31/1/58.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3530691/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23169503 PubMed] |
==EPOCH, dose-escalated {{#subobject:ded061|Regimen=1}}== | ==EPOCH, dose-escalated {{#subobject:ded061|Regimen=1}}== | ||
Line 278: | Line 278: | ||
*[[Vincristine (Oncovin)]] 0.4 mg/m<sup>2</sup>/day IV continuous infusion on days 1 to 4 (total dose per cycle: 1.6 mg/m<sup>2</sup>) | *[[Vincristine (Oncovin)]] 0.4 mg/m<sup>2</sup>/day IV continuous infusion on days 1 to 4 (total dose per cycle: 1.6 mg/m<sup>2</sup>) | ||
*[[Cyclophosphamide (Cytoxan)]] as follows: | *[[Cyclophosphamide (Cytoxan)]] as follows: | ||
− | **CD4+ count | + | **CD4+ count less than 100/uL: 187 mg/m<sup>2</sup> IV over 15 minutes once on day 5 |
− | **CD4+ count | + | **CD4+ count greater than 100/uL: 375 mg/m<sup>2</sup> IV over 15 minutes once on day 5 |
− | **In each subsequent cycle, increase dose | + | **In each subsequent cycle, increase dose by 187 mg/m<sup>2</sup> if the neutrophil nadir is greater than 500/uL and platelet nadir is greater than 25 x 10<sup>9</sup>/L. Decrease dose by 187 mg/m<sup>2</sup> if the neutrophil nadir is less than 500/uL or platelet nadir is less than 25 x 10<sup>9</sup>/L. |
*[[Doxorubicin (Adriamycin)]] 10 mg/m<sup>2</sup>/day IV continuous infusion on days 1 to 4 (total dose per cycle: 40 mg/m<sup>2</sup>) | *[[Doxorubicin (Adriamycin)]] 10 mg/m<sup>2</sup>/day IV continuous infusion on days 1 to 4 (total dose per cycle: 40 mg/m<sup>2</sup>) | ||
====Supportive medications==== | ====Supportive medications==== | ||
− | *[[Filgrastim (Neupogen)]] 5 | + | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting on day 6 and continuing until ANC greater than 5000/uL past nadir |
'''21-day cycle for 6 cycles''' | '''21-day cycle for 6 cycles''' | ||
Line 468: | Line 468: | ||
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895225/ Kaplan et al. 2005 (AMC010)] |
|style="background-color:#00CD00"|Phase III | |style="background-color:#00CD00"|Phase III | ||
|[[#CHOP|CHOP]] | |[[#CHOP|CHOP]] | ||
Line 483: | Line 483: | ||
====Supportive medications==== | ====Supportive medications==== | ||
*Combination antiretrovirals were required | *Combination antiretrovirals were required | ||
− | *[[Filgrastim (Neupogen)|G-CSF]] 5 mcg/kg SC once per day from days 4 to 13 or until ANC | + | *[[Filgrastim (Neupogen)|G-CSF]] 5 mcg/kg SC once per day from days 4 to 13 or until ANC greater than 10k/uL. |
− | *Pneumocystis cariini prophylaxis with | + | *Pneumocystis cariini prophylaxis with ONE of the following: |
**[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Cotrimoxazole]] (dose/schedule not specified) | **[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Cotrimoxazole]] (dose/schedule not specified) | ||
**[[Dapsone (Aczone)]] (dose/schedule not specified) | **[[Dapsone (Aczone)]] (dose/schedule not specified) | ||
Line 560: | Line 560: | ||
===References=== | ===References=== | ||
− | # Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, Levine AM, Scadden DT. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005 Sep 1;106(5):1538-43. Epub 2005 May 24. [http://bloodjournal.hematologylibrary.org/content/106/5/1538.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15914552 PubMed] | + | # Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, Levine AM, Scadden DT. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005 Sep 1;106(5):1538-43. Epub 2005 May 24. [http://bloodjournal.hematologylibrary.org/content/106/5/1538.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895225/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/15914552 PubMed] |
# Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, Billaud E, Raphael M, Lancar R, Costagliola D. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol. 2006 Sep 1;24(25):4123-8. Epub 2006 Aug 8. [http://jco.ascopubs.org/content/24/25/4123.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16896005 PubMed] | # Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, Billaud E, Raphael M, Lancar R, Costagliola D. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol. 2006 Sep 1;24(25):4123-8. Epub 2006 Aug 8. [http://jco.ascopubs.org/content/24/25/4123.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16896005 PubMed] | ||
# Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, López-Guillermo A, Gardella S, López A, Abella E, García M; PETHEMA, GELTAMO, GELCAB and GESIDA Groups. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol. 2008 Feb;140(4):411-9. Epub 2007 Dec 19. [http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2007.06943.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18162120 PubMed] | # Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, López-Guillermo A, Gardella S, López A, Abella E, García M; PETHEMA, GELTAMO, GELCAB and GESIDA Groups. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol. 2008 Feb;140(4):411-9. Epub 2007 Dec 19. [http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2007.06943.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18162120 PubMed] | ||
Line 577: | Line 577: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4497960/ Noy et al. 2015 (AMC 048)] |
|style="background-color:#EEEE00"|Phase II | |style="background-color:#EEEE00"|Phase II | ||
|- | |- | ||
Line 599: | Line 599: | ||
*[[Folinic acid (Leucovorin)]] as follows: | *[[Folinic acid (Leucovorin)]] as follows: | ||
** 200 mg/m<sup>2</sup> IV once 24 hours after [[Methotrexate (MTX)]], then | ** 200 mg/m<sup>2</sup> IV once 24 hours after [[Methotrexate (MTX)]], then | ||
− | ** 25 mg/m<sup>2</sup> IV every 6 hours until methotrexate level is | + | ** 25 mg/m<sup>2</sup> IV every 6 hours until methotrexate level is less than 50 nmol/L |
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 3 | *[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 3 | ||
− | *[[Filgrastim (Neupogen)]] (dose not specified) SC once per day, starting once methotrexate level is | + | *[[Filgrastim (Neupogen)]] (dose not specified) SC once per day, starting once methotrexate level is less than 50 nmol/L (approximately day 18) and continuing until ANC greater than 1000/uL |
====Regimen B: R-IVAC==== | ====Regimen B: R-IVAC==== | ||
Line 622: | Line 622: | ||
# '''Retrospective:''' Barnes JA, Lacasce AS, Feng Y, Toomey CE, Neuberg D, Michaelson JS, Hochberg EP, Abramson JS. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol. 2011 Aug;22(8):1859-64. Epub 2011 Feb 21. [http://annonc.oxfordjournals.org/content/22/8/1859.long link to original article] '''contains partial protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21339382 PubMed] content property of [http://hemonc.org HemOnc.org] | # '''Retrospective:''' Barnes JA, Lacasce AS, Feng Y, Toomey CE, Neuberg D, Michaelson JS, Hochberg EP, Abramson JS. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol. 2011 Aug;22(8):1859-64. Epub 2011 Feb 21. [http://annonc.oxfordjournals.org/content/22/8/1859.long link to original article] '''contains partial protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21339382 PubMed] content property of [http://hemonc.org HemOnc.org] | ||
# '''Retrospective:''' Kassam S, Bower M, Lee SM, de Vos J, Fields P, Gandhi S, Nelson M, Montoto S, Tenant-Flowers M, Burns F, Marcus R, Edwards SG, Cwynarski K. A retrospective, multi-center analysis of treatment intensification for HIV-positive patients with high-risk diffuse large B-cell lymphoma. Leuk Lymphoma. 2013 Sep;54(9):1921-7. Epub 2013 Jan 4. [http://informahealthcare.com/doi/abs/10.3109/10428194.2012.754024 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23206228 PubMed] | # '''Retrospective:''' Kassam S, Bower M, Lee SM, de Vos J, Fields P, Gandhi S, Nelson M, Montoto S, Tenant-Flowers M, Burns F, Marcus R, Edwards SG, Cwynarski K. A retrospective, multi-center analysis of treatment intensification for HIV-positive patients with high-risk diffuse large B-cell lymphoma. Leuk Lymphoma. 2013 Sep;54(9):1921-7. Epub 2013 Jan 4. [http://informahealthcare.com/doi/abs/10.3109/10428194.2012.754024 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23206228 PubMed] | ||
− | # Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E, Ratner L, Wagner-Johnston N, Kaplan L. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015 Jul 9;126(2):160-6. Epub 2015 May 8. [http://www.bloodjournal.org/content/126/2/160 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4497960/ link to PMC article] | + | # Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E, Ratner L, Wagner-Johnston N, Kaplan L. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015 Jul 9;126(2):160-6. Epub 2015 May 8. [http://www.bloodjournal.org/content/126/2/160 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4497960/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25957391 PubMed] |
==R-EPOCH, dose-escalated {{#subobject:3c32e1|Regimen=1}}== | ==R-EPOCH, dose-escalated {{#subobject:3c32e1|Regimen=1}}== | ||
Line 638: | Line 638: | ||
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2858478/ Sparano et al. 2010 (AMC034)] |
|style="background-color:#00CD00"|Randomized Phase II | |style="background-color:#00CD00"|Randomized Phase II | ||
|EPOCH -> R | |EPOCH -> R | ||
Line 651: | Line 651: | ||
*[[Vincristine (Oncovin)]] 0.4 mg/m<sup>2</sup>/day IV continuous infusion on days 1 to 4 (total dose per cycle: 1.6 mg/m<sup>2</sup>) | *[[Vincristine (Oncovin)]] 0.4 mg/m<sup>2</sup>/day IV continuous infusion on days 1 to 4 (total dose per cycle: 1.6 mg/m<sup>2</sup>) | ||
*[[Cyclophosphamide (Cytoxan)]] as follows: | *[[Cyclophosphamide (Cytoxan)]] as follows: | ||
− | **CD4+ count | + | **CD4+ count less than 100/uL: 187 mg/m<sup>2</sup> IV over 15 minutes once on day 5 |
− | **CD4+ count | + | **CD4+ count greater than 100/uL: 375 mg/m<sup>2</sup> IV over 15 minutes once on day 5 |
− | **In each subsequent cycle, increase dose | + | **In each subsequent cycle, increase dose by 187 mg/m<sup>2</sup> if the neutrophil nadir is greater than 500/uL and platelet nadir is greater than 25 x 10<sup>9</sup>/L. Decrease dose by 187 mg/m<sup>2</sup> if the neutrophil nadir is less than 500/uL or platelet nadir is less than 25 x 10<sup>9</sup>/L. |
*[[Doxorubicin (Adriamycin)]] 10 mg/m<sup>2</sup>/day IV continuous infusion on days 1 to 4 (total dose per cycle: 40 mg/m<sup>2</sup>) | *[[Doxorubicin (Adriamycin)]] 10 mg/m<sup>2</sup>/day IV continuous infusion on days 1 to 4 (total dose per cycle: 40 mg/m<sup>2</sup>) | ||
====Supportive medications==== | ====Supportive medications==== | ||
− | *EITHER [[Filgrastim (Neupogen)]] 5 | + | *EITHER [[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting 24 hours after EPOCH is completed and continuing until "neutrophil recovery"—no absolute count specified |
*OR [[Pegfilgrastim (Neulasta)]] 6 mg SC once 24 hours after EPOCH is completed | *OR [[Pegfilgrastim (Neulasta)]] 6 mg SC once 24 hours after EPOCH is completed | ||
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] 160/800 mg PO TIW (e.g. Monday, Wednesday, Friday) | *[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] 160/800 mg PO TIW (e.g. Monday, Wednesday, Friday) | ||
Line 667: | Line 667: | ||
===References=== | ===References=== | ||
− | # Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH, Von Roenn J, Dezube BJ, Remick SC, Shah MH, Leichman L, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R; AIDS Malignancy Consortium. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010 Apr 15;115(15):3008-16. Epub 2009 Dec 18. [http://bloodjournal.hematologylibrary.org/content/115/15/3008.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20023215 PubMed] | + | # Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH, Von Roenn J, Dezube BJ, Remick SC, Shah MH, Leichman L, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R; AIDS Malignancy Consortium. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010 Apr 15;115(15):3008-16. Epub 2009 Dec 18. [http://bloodjournal.hematologylibrary.org/content/115/15/3008.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2858478/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20023215 PubMed] |
==SC-EPOCH-RR {{#subobject:8d6ea0|Regimen=1}}== | ==SC-EPOCH-RR {{#subobject:8d6ea0|Regimen=1}}== | ||
Line 681: | Line 681: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2858473/ Dunleavy et al. 2010] |
|style="background-color:#EEEE00"|Phase II | |style="background-color:#EEEE00"|Phase II | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901044/ Dunleavy et al. 2013] |
|style="background-color:#ff0000"|Phase II, <20 pts in this arm | |style="background-color:#ff0000"|Phase II, <20 pts in this arm | ||
|- | |- | ||
Line 698: | Line 698: | ||
*[[Doxorubicin (Adriamycin)]] 10 mg/m<sup>2</sup>/day IV continuous infusion on days 1 to 4 (total dose per cycle: 40 mg/m2) | *[[Doxorubicin (Adriamycin)]] 10 mg/m<sup>2</sup>/day IV continuous infusion on days 1 to 4 (total dose per cycle: 40 mg/m2) | ||
− | Dose modifications | + | ====Dose modifications==== |
− | *[[Cyclophosphamide (Cytoxan)]] | + | *[[Cyclophosphamide (Cytoxan)]]: |
− | **In the subsequent cycle, decrease dose | + | **In the subsequent cycle, decrease dose by 187 mg/m<sup>2</sup> if ANC was less than 500/uL for 2 to 4 days or platelets were less than 25 x 10<sup>9</sup>/L for 2 to 4 days. |
− | **In the subsequent cycle, decrease dose | + | **In the subsequent cycle, decrease dose by 375 mg/m<sup>2</sup> if ANC was less than 500/uL for 5 or more days or platelets were less than 25 x 10<sup>9</sup>/L for 5 or more days. |
− | **If | + | **If dose-reduced in prior cycle, increase dose by 187 mg/m2, up to maximum of 750 mg/m2, if ANC was greater than 500/uL and platelets were greater than 25 x 10<sup>9</sup>/L for the entire cycle. |
====CNS prophylaxis==== | ====CNS prophylaxis==== | ||
Line 708: | Line 708: | ||
====Supportive medications==== | ====Supportive medications==== | ||
− | *[[Filgrastim (Neupogen)]] 300 mcg SC once per day starting on day 6, continue until ANC | + | *[[Filgrastim (Neupogen)]] 300 mcg SC once per day starting on day 6, continue until ANC greater than 5k/uL above nadir |
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] 160/800 mg PO TIW (e.g. Monday, Wednesday, Friday) | *[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] 160/800 mg PO TIW (e.g. Monday, Wednesday, Friday) | ||
*[[Omeprazole (Prilosec)]] 20 mg PO once per day (or equivalent) | *[[Omeprazole (Prilosec)]] 20 mg PO once per day (or equivalent) | ||
Line 717: | Line 717: | ||
===References=== | ===References=== | ||
− | # Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS, Carrasquillo JA, Steinberg SM, Yarchoan R, Jaffe ES, Wilson WH. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010 Apr 15;115(15):3017-24. Epub 2010 Feb 3. [http://bloodjournal.hematologylibrary.org/content/115/15/3017.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20130244 PubMed] | + | # Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS, Carrasquillo JA, Steinberg SM, Yarchoan R, Jaffe ES, Wilson WH. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010 Apr 15;115(15):3017-24. Epub 2010 Feb 3. [http://bloodjournal.hematologylibrary.org/content/115/15/3017.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2858473/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20130244 PubMed] |
− | # Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, Widemann B, Staudt LM, Jaffe ES, Little RF, Wilson WH. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013 Nov 14;369(20):1915-25. [http://www.nejm.org/doi/full/10.1056/NEJMoa1308392 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24224624 PubMed] | + | # Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, Widemann B, Staudt LM, Jaffe ES, Little RF, Wilson WH. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013 Nov 14;369(20):1915-25. [http://www.nejm.org/doi/full/10.1056/NEJMoa1308392 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901044/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24224624 PubMed] |
==Stanford V {{#subobject:c00372|Regimen=1}}== | ==Stanford V {{#subobject:c00372|Regimen=1}}== | ||
Line 772: | Line 772: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5000843/ Alvarnas et al. 2016 (BMT CTN 0803/AMC 071)] |
|style="background-color:#EEEE00"|Phase II | |style="background-color:#EEEE00"|Phase II | ||
|- | |- | ||
Line 786: | Line 786: | ||
===References=== | ===References=== | ||
# Re A, Cattaneo C, Michieli M, Casari S, Spina M, Rupolo M, Allione B, Nosari A, Schiantarelli C, Vigano M, Izzi I, Ferremi P, Lanfranchi A, Mazzuccato M, Carosi G, Tirelli U, Rossi G. High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol. 2003 Dec 1;21(23):4423-7. Epub 2003 Oct 27. Erratum in: J Clin Oncol. 2004 Jan 15;22(2):386. Mazzuccato Maurizio [corrected to Mazzuccato Mauro]. [http://jco.ascopubs.org/content/21/23/4423.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14581441 PubMed] | # Re A, Cattaneo C, Michieli M, Casari S, Spina M, Rupolo M, Allione B, Nosari A, Schiantarelli C, Vigano M, Izzi I, Ferremi P, Lanfranchi A, Mazzuccato M, Carosi G, Tirelli U, Rossi G. High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol. 2003 Dec 1;21(23):4423-7. Epub 2003 Oct 27. Erratum in: J Clin Oncol. 2004 Jan 15;22(2):386. Mazzuccato Maurizio [corrected to Mazzuccato Mauro]. [http://jco.ascopubs.org/content/21/23/4423.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14581441 PubMed] | ||
− | # Alvarnas JC, Le Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, Devine S, Baiocchi R, Lozanski G, Kaplan L, Noy A, Popat U, Hsu J, Morris LE Jr, Thompson J, Horowitz MM, Mendizabal A, Levine A, Krishnan A, Forman SJ, Navarro WH, Ambinder R. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. Blood. 2016 Aug 25;128(8):1050-8. Epub 2016 Jun 13. [http://www.bloodjournal.org/content/128/8/1050.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27297790 PubMed] | + | # Alvarnas JC, Le Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, Devine S, Baiocchi R, Lozanski G, Kaplan L, Noy A, Popat U, Hsu J, Morris LE Jr, Thompson J, Horowitz MM, Mendizabal A, Levine A, Krishnan A, Forman SJ, Navarro WH, Ambinder R. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. Blood. 2016 Aug 25;128(8):1050-8. Epub 2016 Jun 13. [http://www.bloodjournal.org/content/128/8/1050.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5000843/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27297790 PubMed] |
[[Category:HIV-associated lymphoma regimens]] | [[Category:HIV-associated lymphoma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Disease index]] | [[Category:Disease index]] |
Revision as of 16:25, 26 July 2017
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
19 regimens on this page
25 variants on this page
|
The most common HIV-associated lymphomas are of DLBCL or Burkitt lymphoma histology; plasmablastic lymphoma and primary effusion lymphomas are also frequently seen in advanced-stage HIV/AIDS. In patients with a normal CD4+ T-cell count and well-controlled HIV, the lymphoma is typically treated as per the histologic subtype. For others, regimens specific to HIV-associated lymphoma have been developed and are included here.
Untreated
CHOP
back to top |
CHOP: Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Prednisone
Synonyms: CHOP-21, ACOP, CAVP, COPA, VACP, VCAP
Structured Concept: C9549 (NCI-T), C0055598 (NCI-MT/UMLS)
Regimen
Study | Evidence | Comparator | Efficacy |
Kaplan et al. 2005 (AMC010) | Phase III | R-CHOP | Seems not superior |
Chemotherapy
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg per cycle) IV once on day 1
- Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5
Supportive medications
- Combination antiretrovirals were required
- G-CSF 5 mcg/kg SC once per day from days 4 to 13 or until ANC greater than 10k/uL.
- Pneumocystis cariini prophylaxis with ONE of the following:
- Cotrimoxazole (dose/route/schedule not specified)
- Dapsone (Aczone) (dose/route/schedule not specified)
- Pentamidine (Nebupent) (dose/schedule not specified)
21-day cycle for 3 cycles for early disease, or minimum of 6 cycles or 2 past CR for advanced disease
Radiation therapy
Patients with stage I, IE, or nonbulky stage II disease received "involved field radiotherapy to a total dose of at least 4000 cGy beginning 3 weeks after the third cycle of chemotherapy."
References
- Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, Levine AM, Scadden DT. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005 Sep 1;106(5):1538-43. Epub 2005 May 24. link to original article contains verified protocol link to PMC article PubMed
CODOX-M/IVAC
back to top |
CODOX-M: Cyclophosphamide, Oncovin, DOXorubicin, Methotrexate
IVAC: Ifosfamide, Vepesid (etoposide), Ara-C (cytarabine)
Regimen
Study | Evidence |
Magrath et al. 1996 (77-04) | Phase II |
Wang et al. 2003 | Retrospective |
Note: the original protocol of Magrath et al. 1996 did not comment on HIV status. Wang et al. 2003 retrospectively identified 8 HIV+ Burkitt lymphoma patients who had undergone treatment with CODOX-M/IVAC.
- Patients are stratified into high and low risk:
- Low risk patients must fulfill all of the following criteria:
- Serum LDH within the institution's normal range (for the NCI, this was less than 350 IU/L)
- Single extraabdominal mass or completely resected abdominal disease
- Any patients which do not meet low risk criteria are classified as high risk
- Low risk patients must fulfill all of the following criteria:
Part A: CODOX-M for high risk patients
- Cyclophosphamide (Cytoxan) 800 mg/m2 IV once on day 1, then 200 mg/m2 IV once per day on days 2 to 5
- Vincristine (Oncovin) as follows:
- Cycle 1: 1.5 mg/m2 IV once per day on days 1 & 8
- Cycle 3: 1.5 mg/m2 IV once per day on days 1, 8, 15
- Doxorubicin (Adriamycin) 40 mg/m2 IV once on day 1
- Methotrexate (MTX) 1200 mg/m2 IV over 1 hour on day 10, then 240 mg/m2/hour IV over 23 hours on day 10 (total dose per cycle: 6720 mg/m2)
CNS prophylaxis
- Cytarabine (Cytosar) 70 mg intrathecal once per day on days 1 & 3
- Patients younger than 3 years old received "appropriately reduced doses"
- Methotrexate (MTX) 12 mg intrathecal once on day 15
- Patients younger than 3 years old received "appropriately reduced doses"
Patients with CNS disease at presentation received the following extra doses of intrathecal chemotherapy during cycle 1:
- Cytarabine (Cytosar) 70 mg intrathecal once on day 5 (in addition to doses above)
- Methotrexate (MTX) 12 mg intrathecal once on day 17 (in addition to dose above)
Supportive medications
- Folinic acid (Leucovorin) 192 mg/m2 IV once on day 11, starting 36 hours after the start of the day 10 Methotrexate (MTX), then 12 mg/m2 IV every 6 hours thereafter until serum methotrexate level is less than 50 nmol/L
- GM-CSF 7.5 mcg/kg SC once per day, starting on day 13 and continuing until ANC greater than 1000/uL
Part A: CODOX-M for low risk patients
- Cyclophosphamide (Cytoxan) 800 mg/m2 IV once on day 1, then 200 mg/m2 IV once per day on days 2 to 5
- Vincristine (Oncovin) 1.5 mg/m2 IV once per day on days 1 & 8
- Doxorubicin (Adriamycin) 40 mg/m2 IV once on day 1
- Methotrexate (MTX) 1200 mg/m2 IV over 1 hour on day 10, then 240 mg/m2/hour IV over 23 hours on day 10 (total dose per cycle: 6720 mg/m2)
CNS prophylaxis
- Cytarabine (Cytosar) 70 mg intrathecal once on day 1
- Patients younger than 3 years old received "appropriately reduced doses"
- Methotrexate (MTX) 12 mg intrathecal once on day 3
- Patients younger than 3 years old received "appropriately reduced doses"
Supportive medications
- Folinic acid (Leucovorin) 192 mg/m2 IV once on day 11, starting 36 hours after the start of the day 10 Methotrexate (MTX), then 12 mg/m2 IV every 6 hours thereafter until serum methotrexate level is less than 50 nmol/L
- No GM-CSF used for low risk patients
Part B: IVAC for high risk patients
- Ifosfamide (Ifex) 1500 mg/m2 IV once per day on days 1 to 5
- Etoposide (Vepesid) 60 mg/m2 IV once per day on days 1 to 5
- Cytarabine (Cytosar) 2000 mg/m2 IV every 12 hours on days 1 & 2 (total of 4 doses per cycle)
CNS prophylaxis
- Methotrexate (MTX) 12 mg intrathecal once on day 5
Patients with CNS disease at presentation received the following extra doses of intrathecal chemotherapy during cycle 2:
- Cytarabine (Cytosar) 70 mg intrathecal once per day on days 7 & 9
- Methotrexate (MTX) 12 mg intrathecal once on day 17 (in addition to dose above)
Supportive medications
- Mesna (Mesnex) 360 mg/m2 IV every 3 hours on days 1 to 5, given at same time as Ifosfamide (Ifex)
- GM-CSF 7.5 mcg/kg SC once per day, starting on day 7 and continuing until ANC greater than 1000/uL
High risk patients receive Part A: CODOX-M and Part B: IVAC given in an alternating fashion x total of 4 cycles (A, B, A, B). Low risk patients receive Part A: CODOX-M x 3 cycles only. Each cycle starts on the same day that the patient's ANC is greater than 1000/uL.
References
- Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J, Neely J, Arndt C, Nieder M, Jaffe E, Wittes RA, Horak ID. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996 Mar;14(3):925-34. link to original article contains verified protocol PubMed
- Wang ES, Straus DJ, Teruya-Feldstein J, Qin J, Portlock C, Moskowitz C, Goy A, Hedrick E, Zelenetz AD, Noy A. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer. 2003 Sep 15;98(6):1196-205. link to original article contains verified protocol PubMed
dmCODOX-M/IVAC - Modified Magrath
back to top |
dmCODOX-M: dose-modified Cyclophosphamide, Oncovin, DOXorubicin, Methotrexate
IVAC: Ifosfamide, Vepesid (etoposide), Ara-C (cytarabine)
Regimen
Study | Evidence |
Mead et al. 2008 (MRC/NCRI LY10) | Non-randomized |
- Patients are stratified into high and low risk:
- Low risk patients must fulfill at least 3 of the following criteria:
- Normal LDH
- WHO performance status of 0 or 1
- Ann Arbor stage I or II
- 0 or 1 extranodal sites of disease
- Any patients which do not meet low risk criteria are classified as high risk
- Low risk patients must fulfill at least 3 of the following criteria:
Part A: dmCODOX-M
- Cyclophosphamide (Cytoxan) 800 mg/m2 IV once on day 1, then 200 mg/m2 IV once per day on days 2 to 5
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg per cycle) IV once per day on days 1 & 8
- Doxorubicin (Adriamycin) 40 mg/m2 IV once on day 1
- Methotrexate (MTX) as follows:
- Patients 65 years old or younger: 300 mg/m2 IV over 1 hour on day 10, then 2700 mg/m2 IV over 23 hours on day 10 (total dose per cycle: 3000 mg/m2)
- Patients older than 65 years old: 100 mg/m2 IV over 1 hour on day 10, then 900 mg/m2 IV over 23 hours on day 10 (total dose per cycle: 1000 mg/m2)
CNS prophylaxis
- Cytarabine (Cytosar) 70 mg intrathecal once per day on days 1 & 3
- Methotrexate (MTX) 12 mg intrathecal once on day 15
Patients with CNS disease at presentation received the following extra doses of intrathecal chemotherapy:
- Cytarabine (Cytosar) 70 mg intrathecal once on day 5 (in addition to doses above)
- Methotrexate (MTX) 12 mg intrathecal once on day 17 (in addition to dose above)
- Folinic acid (Leucovorin) 15 mg PO once on day 18, 24 hours after intrathecal Methotrexate (MTX)
Supportive medications
- Folinic acid (Leucovorin) 15 mg/m2 IV every 3 hours x 5 doses on day 11, starting 36 hours after start of the day 10 Methotrexate (MTX), then 15 mg/m2 IV every 6 hours until methotrexate level is less than 50 nmol/L
- Folinic acid (Leucovorin) 15 mg PO once on day 16, 24 hours after intrathecal Methotrexate (MTX)
- Filgrastim (Neupogen) 5 mcg/kg SC once per day, starting on day 13 and continuing until ANC greater than 1000/uL
- Allopurinol (Zyloprim) PO and/or Rasburicase (Elitek) prior to starting chemotherapy
Part B: IVAC
- Ifosfamide (Ifex) as follows:
- Patients 65 years old or younger: 1500 mg/m2 IV over 1 hour once per day on days 1 to 5
- Patients older than 65 years old: 1000 mg/m2 IV over 1 hour once per day on days 1 to 5
- Etoposide (Vepesid) 60 mg/m2 IV over 1 hour once per day on days 1 to 5
- Cytarabine (Cytosar) as follows:
- Patients 65 years old or younger: 2000 mg/m2 IV over 3 hours every 12 hours on days 1 & 2 (total of 4 doses per cycle)
- Patients older than 65 years old: 1000 mg/m2 IV over 3 hours every 12 hours on days 1 & 2 (total of 4 doses per cycle)
CNS prophylaxis
- Methotrexate (MTX) 12 mg intrathecal once on day 5
Supportive medications
- Mesna (Mesnex) as follows:
- Patients 65 years old or younger: 300 mg/m2 (mixed with Ifosfamide (Ifex)) IV over 1 hour on days 1 to 5, then 300 mg/m2 IV every four hours x 2 doses on days 1 to 5
- Patients older than 65 years old: 200 mg/m2 (mixed with Ifosfamide (Ifex)) IV over 1 hour on days 1 to 5, then 200 mg/m2 IV every four hours x 2 doses on days 1 to 5
- Folinic acid (Leucovorin) 15 mg PO once on day 6, 24 hours after intrathecal Methotrexate (MTX)
- Filgrastim (Neupogen) 5 mcg/kg SC once per day, starting on day 7 and continuing until ANC greater than 1000/uL
High risk patients receive Part A: dmCODOX-M and Part B: IVAC given in an alternating fashion x total of 4 cycles (A, B, A, B). Low risk patients receive Part A: dmCODOX-M x 3 cycles only. Each cycle starts on the same day that the patient's ANC is greater than 1000/uL and unsupported (that is, without transfusion) platelet count greater than 75 x 109/L
References
- Mead GM, Barrans SL, Qian W, Walewski J, Radford JA, Wolf M, Clawson SM, Stenning SP, Yule CL, Jack AS; UK National Cancer Research Institute Lymphoma Clinical Studies Group; Australasian Leukaemia and Lymphoma Group. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008 Sep 15;112(6):2248-60. Epub 2008 Jul 8. link to original article contains verified protocol link to PMC article PubMed
DR-COP
back to top |
DR-COP: Doxil (pegylated liposomal doxorubicin), Rituximab, Cyclophosphamide, Oncovin, Prednisone
Regimen
Study | Evidence |
Levine et al. 2012 (AMC047) | Phase II |
Chemotherapy
- Doxorubicin liposomal (Doxil) 40 mg/m2 IV once on day 1
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg per cycle) IV once on day 1
- Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5
- "CNS prophylaxis was mandated in patients with involvement of bone marrow, testis, sinuses, or epidural regions and with stage IV and/or = two extranodal sites, with specific regimen left to physician discretion."
- Highly Active Antiretroviral Therapy (HAART) required; specific regimen left to physician discretion. Use of zidovudine was not allowed.
Supportive medications
- Filgrastim (Neupogen) OR Pegfilgrastim (Neulasta) OR Sargramostim (Leukine) starting on day 3, to continue until beyond nadir of blood counts
- Erythropoietin (e.g. Epoetin alfa (Procrit) or Darbepoetin alfa (Aranesp)) at physician discretion
- PCP prophylaxis required
- Oral quinolone if CD4 cell count less than or equal to 100 and absolute neutrophil count (ANC) less than 500/uL at entry or during treatment
21 to 28 day cycle for up to 6 cycles
References
- Levine AM, Noy A, Lee JY, Tam W, Ramos JC, Henry DH, Parekh S, Reid EG, Mitsuyasu R, Cooley T, Dezube BJ, Ratner L, Cesarman E, Tulpule A. Pegylated Liposomal Doxorubicin, Rituximab, Cyclophosphamide, Vincristine, and Prednisone in AIDS-Related Lymphoma: AIDS Malignancy Consortium Study 047. J Clin Oncol. 2013 Jan 1;31(1):58-64. Epub 2012 Nov 19. link to original article contains verified protocol link to PMC article PubMed
EPOCH, dose-escalated
back to top |
EPOCH: Etoposide, Prednisone, Oncovin (Vincristine), Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin)
Regimen
Study | Evidence |
Little et al. 2003 | Non-randomized |
Note: the paper refers to this regimen as dose-adjusted EPOCH but to avoid confusion with the other version of dose-adjusted EPOCH, we refer to it as dose-escalated EPOCH, here.
Chemotherapy
- Etoposide (Vepesid) 50 mg/m2/day IV continuous infusion on days 1 to 4 (total dose per cycle: 200 mg/m2)
- Prednisone (Sterapred) 60 mg/m2 PO once per day on days 1 to 5
- Vincristine (Oncovin) 0.4 mg/m2/day IV continuous infusion on days 1 to 4 (total dose per cycle: 1.6 mg/m2)
- Cyclophosphamide (Cytoxan) as follows:
- CD4+ count less than 100/uL: 187 mg/m2 IV over 15 minutes once on day 5
- CD4+ count greater than 100/uL: 375 mg/m2 IV over 15 minutes once on day 5
- In each subsequent cycle, increase dose by 187 mg/m2 if the neutrophil nadir is greater than 500/uL and platelet nadir is greater than 25 x 109/L. Decrease dose by 187 mg/m2 if the neutrophil nadir is less than 500/uL or platelet nadir is less than 25 x 109/L.
- Doxorubicin (Adriamycin) 10 mg/m2/day IV continuous infusion on days 1 to 4 (total dose per cycle: 40 mg/m2)
Supportive medications
- Filgrastim (Neupogen) 5 mcg/kg SC once per day, starting on day 6 and continuing until ANC greater than 5000/uL past nadir
21-day cycle for 6 cycles
References
- Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, Franchini G, Gutierrez M, Raffeld M, Jaffe ES, Shearer G, Yarchoan R, Wilson WH. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003 Jun 15;101(12):4653-9. Epub 2003 Feb 27. link to original article contains verified protocol PubMed
GMALL-R
back to top |
GMALL-R: German Multicenter Study Group for the Treatment of Adult Acute Lymphoblastic Leukemia, Rituximab
Regimen
Study | Evidence |
Ribera et al. 2013 (Burkimab) | Phase II |
Numbering of days is based on prephase->A->B->C; however, certain patient populations received different ordering of regimen, see below.
Prephase
- Cyclophosphamide (Cytoxan) 200 mg/m2 IV over 1 hour once per day on days 1 to 5
- Prednisone (Sterapred) 60 mg/m2 IV bolus once per day on days 1 to 5
Cycle A
- Rituximab (Rituxan) 375 mg/m2 IV over 4 hours once on day 7
- Vincristine (Oncovin) 2 mg IV bolus once on day 8
- Methotrexate (MTX) 1500 mg/m2 IV over 24 hours once on day 8
- Older than 55 years: reduce dose by 50%
- Ifosfamide (Ifex) 800 mg/m2 IV over 1 hour once per day on days 8 to 12
- Dexamethasone (Decadron) 10 mg/m2 IV bolus once per day on days 8 to 12
- Teniposide (Vumon) 100 mg/m2 IV over 1 hour once per day on days 11 & 12
- Cytarabine (Cytosar) 150 mg/m2 IV over 1 hour BID on days 11 & 12
- Older than 55 years: reduce dose by 50%
Supportive medications
- Folinic acid (Leucovorin) (dose/route/schedule not specified), starting 12 hours after Methotrexate (MTX) infusion
Cycle B
- Rituximab (Rituxan) 375 mg/m2 IV over 4 hours once on day 28
- Vincristine (Oncovin) 2 mg IV bolus once on day 29
- Methotrexate (MTX) 1500 mg/m2 IV over 24 hours once on day 29
- Older than 55 years: reduce dose by 50%
- Cyclophosphamide (Cytoxan) 200 mg/m2 IV over 1 hour once per day on days 29 to 33
- Dexamethasone (Decadron) 10 mg/m2 IV bolus once per day on days 29 to 33
- Doxorubicin (Adriamycin) 25 mg/m2 IV over 15 minutes once per day on days 32 & 33
Supportive medications
- Folinic acid (Leucovorin) (dose/route/schedule not specified), starting 12 hours after Methotrexate (MTX) infusion
Cycle C
- Rituximab (Rituxan) 375 mg/m2 IV over 4 hours once on day 49
- Vindesine (Eldisine) 3 mg/m2 (maximum dose 5 mg) IV bolus once on day 50
- Methotrexate (MTX) 1500 mg/m2 IV over 24 hours once on day 50
- Older than 55 years: reduce dose by 50%
- Dexamethasone (Decadron) 10 mg/m2 IV bolus once per day on days 50 to 54
- Etoposide (Vepesid) 250 mg/m2 IV over 1 hour once per day on days 53 & 54
- Cytarabine (Cytosar) 2000 mg/m2 IV over 3 hours BID on day 54
- Older than 55 years: reduce dose by 50%
Supportive medications
- Folinic acid (Leucovorin) (dose/route/schedule not specified), starting 12 hours after Methotrexate (MTX) infusion
Give regimen as follows:
- Advanced stage and younger than 55 years: A->B->C x 2 courses (6 total cycles)
- Older than 55 years: Alternate A & B x 3 courses (6 total cycles)
- Localized stage: 4 total cycles (unclear from protocol if this means A alternating with B or A->B->C->A)
CNS Prophylaxis
- Methotrexate (MTX) 15 mg intrathecal once per day on days 1, 8, 12, 29, 33
- Cytarabine (Cytosar) 40 mg intrathecal once per day on days 1, 8, 12, 29, 33
- Dexamethasone (Decadron) 20 mg intrathecal once per day on days 1, 8, 12, 29, 33
8 doses total
References
- Ribera JM, García O, Grande C, Esteve J, Oriol A, Bergua J, González-Campos J, Vall-Llovera F, Tormo M, Hernández-Rivas JM, García D, Brunet S, Alonso N, Barba P, Miralles P, Llorente A, Montesinos P, Moreno MJ, Hernández-Rivas JÁ, Bernal T. Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). Cancer. 2013 May 1;119(9):1660-8. Epub 2013 Jan 29. link to original article contains verified protocol PubMed
LMB86
back to top |
To be completed
References
- Galicier L, Fieschi C, Borie R, Meignin V, Daniel MT, Gérard L, Oksenhendler E. Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood. 2007 Oct 15;110(8):2846-54. Epub 2007 Jul 3. link to original article PubMed
m-BACOD
back to top |
m-BACOD: methotrexate (moderate dose), Bleomycin, Adriamycin (Doxorubicin), Cyclophosphamide, Oncovin (Vincristine), Dexamethasone
Structured Concept: C63458 (NCI-T), C1883662 (NCI-MT/UMLS)
Regimen #1, "low-dose"
Study | Evidence | Comparator | Efficacy |
Kaplan et al. 1997 | Phase III | Standard-dose m-BACOD | Seems not superior |
Note: this is of historical interest, only.
Chemotherapy
- Methotrexate (MTX) 200 mg/m2 IV once on day 15
- Bleomycin (Blenoxane) 4 units/m2 IV once on day 1
- Doxorubicin (Adriamycin) 25 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 300 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 IV once on day 1
- Dexamethasone (Decadron) 3 mg/m2 PO once per day on days 1 to 5
Supportive medications
- GM-CSF 5 mcg/kg SC once per day on days 4 to 13 (as needed)
CNS prophylaxis
- Cytarabine (Cytosar) 50 mg IT once per day on days 1, 8, 15, 22 of cycle 1, only
21-day cycle for 2 cycles past complete remission (minimum of 4 cycles)
Regimen #2, "standard-dose"
Study | Evidence | Comparator | Efficacy |
Kaplan et al. 1997 | Phase III | Low-dose m-BACOD | Seems not superior |
Note: this is of historical interest, only.
Chemotherapy
- Methotrexate (MTX) 200 mg/m2 IV once on day 15
- Bleomycin (Blenoxane) 4 units/m2 IV once on day 1
- Doxorubicin (Adriamycin) 45 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 600 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 IV once on day 1
- Dexamethasone (Decadron) 6 mg/m2 PO once per day on days 1 to 5
Supportive medications
- GM-CSF 5 mcg/kg SC once per day on days 4 to 13
CNS prophylaxis
- Cytarabine (Cytosar) 50 mg IT once per day on days 1, 8, 15, 22 of cycle 1, only
21-day cycle for 2 cycles past complete remission (minimum of 4 cycles)
References
- Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP, Herndier B, Northfelt DW, Huang J, Tulpule A, Levine AM. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997 Jun 5;336(23):1641-8. link to original article contains verified protocol PubMed
R-CHOP
back to top |
R-CHOP: Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone
Synonyms: R-CHOP-21, CHOP-R
Structured Concept: C9760 (NCI-T), C0393023 (NCI-MT/UMLS)
Regimen #1
Study | Evidence | Comparator | Efficacy |
Kaplan et al. 2005 (AMC010) | Phase III | CHOP | Seems not superior |
Chemotherapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day -2
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg per cycle) IV once on day 1
- Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5
Supportive medications
- Combination antiretrovirals were required
- G-CSF 5 mcg/kg SC once per day from days 4 to 13 or until ANC greater than 10k/uL.
- Pneumocystis cariini prophylaxis with ONE of the following:
- Cotrimoxazole (dose/schedule not specified)
- Dapsone (Aczone) (dose/schedule not specified)
- Pentamidine (Nebupent) (dose/schedule not specified)
21-day cycle for 3 cycles for early disease, or minimum of 6 cycles or 2 past CR for advanced disease
Radiation therapy
Patients with stage I, IE, or nonbulky stage II disease received "involved field radiotherapy to a total dose of at least 4000 cGy beginning 3 weeks after the third cycle of chemotherapy."
Maintenance
Partial or complete responders received:
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Monthly x 3 doses
Regimen #2
Study | Evidence |
Ribera et al. 2007x | Phase II |
Chemotherapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg per cycle) IV once on day 1
- Prednisone (Sterapred) 40 mg/m2 PO once per day on days 1 to 5
CNS prophylaxis
To be given with each cycle; day of administration not reported.
- Methotrexate (MTX) 12 mg intrathecal
- Cytarabine (Cytosar) 40 mg intrathecal
- Hydrocortisone (Cortef) 20 mg intrathecal
Supportive medications
- Combination antiretrovirals were required: one or two protease inhibitors and two nucleoside reverse transcriptase inhibitors
- Pneumocystis cariini prophylaxis with either:
- Cotrimoxazole 160/800 mg PO TIW
- Pentamidine (Nebupent) 300 mg inhaled (schedule not specified)
21-day cycle for 6 cycles
Radiation therapy
Patients with bulky disease or a residual mass received involved field radiotherapy (details not provided).
Regimen #3
Study | Evidence |
Boué et al. 2006 | Phase II |
Chemotherapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day -1 (cycle 1; subsequent cycles ok to give on day 1 if tolerated)
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg per cycle) IV once on day 1
- Prednisone (Sterapred) 40 mg/m2 PO once per day on days 1 to 5
CNS prophylaxis
Decision was left to individual centers.
Supportive medications
- Antiretrovirals were recommended
- Pneumocystis cariini prophylaxis was recommended with Cotrimoxazole (dose/schedule not specified)
21-day cycle for 6 cycles
References
- Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, Levine AM, Scadden DT. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005 Sep 1;106(5):1538-43. Epub 2005 May 24. link to original article contains verified protocol link to PMC article PubMed
- Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, Billaud E, Raphael M, Lancar R, Costagliola D. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol. 2006 Sep 1;24(25):4123-8. Epub 2006 Aug 8. link to original article contains verified protocol PubMed
- Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, López-Guillermo A, Gardella S, López A, Abella E, García M; PETHEMA, GELTAMO, GELCAB and GESIDA Groups. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol. 2008 Feb;140(4):411-9. Epub 2007 Dec 19. link to original article contains verified protocol PubMed
R-CODOX-M/R-IVAC
back to top |
R-dmCODOX-M: Rituximab, dose-modified Cyclophosphamide, Oncovin (Vincristine), DOXorubicin, Methotrexate
R-IVAC: Rituximab, Ifosfamide, Vepesid (Etoposide), Ara-C (Cytarabine)
Regimen
Study | Evidence |
Noy et al. 2015 (AMC 048) | Phase II |
Intended for HIV-associated Burkitt lymphoma, and the first published prospective regimen to explicitly use rituximab. This is sometimes called modified Magrath but is in fact a second modification to the modified Magrath described by Lacasce et al. 2004.
Regimen A: R-CODOX-M
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 800 mg/m2 IV once per day on days 1 & 2
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once per day on days 1 & 8
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Methotrexate (MTX) 3000 mg/m2 IV once on day 15
CNS prophylaxis
- Cytarabine (Cytosar) 50 mg intrathecal as follows:
- Once on day 1
- High-risk disease only: once on day 3
- Methotrexate (MTX) 12 mg intrathecal once on day 1 (admixed with Cytarabine and Hydrocortisone (Cortef) 50 mg)
Supportive medications
- Folinic acid (Leucovorin) as follows:
- 200 mg/m2 IV once 24 hours after Methotrexate (MTX), then
- 25 mg/m2 IV every 6 hours until methotrexate level is less than 50 nmol/L
- Pegfilgrastim (Neulasta) 6 mg SC once on day 3
- Filgrastim (Neupogen) (dose not specified) SC once per day, starting once methotrexate level is less than 50 nmol/L (approximately day 18) and continuing until ANC greater than 1000/uL
Regimen B: R-IVAC
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
- Ifosfamide (Ifex) 1500 mg/m2/day IV continuous infusion on days 1 to 5
- Etoposide (Vepesid) 60 mg/m2/day IV continuous infusion on days 1 to 5
- Cytarabine (Cytosar) 2000 mg/m2 IV every 12 hours on days 1 & 2 (total of 4 doses per cycle)
CNS prophylaxis
- Methotrexate (MTX) 12 mg intrathecal once on day 5
Supportive medications
- Mesna (Mesnex) 1500 mg/m2/day IV continuous infusion on days 1 to 5
- Pegfilgrastim (Neulasta) 6 mg SC once on day 6
Low-risk patients received 3 cycles of regimen A (R-CODOX-M); high-risk patients received 4 alternating cycles (A -> B -> A -> B)
References
- Lacasce A, Howard O, Lib S, Fisher D, Weng A, Neuberg D, Shipp M. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma. 2004 Apr;45(4):761-7. link to original article contains verified protocol PubMed
- Retrospective: Barnes JA, Lacasce AS, Feng Y, Toomey CE, Neuberg D, Michaelson JS, Hochberg EP, Abramson JS. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol. 2011 Aug;22(8):1859-64. Epub 2011 Feb 21. link to original article contains partial protocol PubMed content property of HemOnc.org
- Retrospective: Kassam S, Bower M, Lee SM, de Vos J, Fields P, Gandhi S, Nelson M, Montoto S, Tenant-Flowers M, Burns F, Marcus R, Edwards SG, Cwynarski K. A retrospective, multi-center analysis of treatment intensification for HIV-positive patients with high-risk diffuse large B-cell lymphoma. Leuk Lymphoma. 2013 Sep;54(9):1921-7. Epub 2013 Jan 4. link to original article PubMed
- Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E, Ratner L, Wagner-Johnston N, Kaplan L. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015 Jul 9;126(2):160-6. Epub 2015 May 8. link to original article contains verified protocol link to PMC article PubMed
R-EPOCH, dose-escalated
back to top |
R-EPOCH: Rituximab, Etoposide, Prednisone, Oncovin (Vincristine), Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin)
Regimen
Study | Evidence | Comparator | Efficacy |
Sparano et al. 2010 (AMC034) | Randomized Phase II | EPOCH -> R | Not reported |
Note: using Fisher's exact test, the two-tailed P-value equals 0.1429.
Chemotherapy
- Rituximab (Rituxan) 375 mg/m2 IV once "before each EPOCH cycle"
- Etoposide (Vepesid) 50 mg/m2/day IV continuous infusion on days 1 to 4 (total dose per cycle: 200 mg/m2)
- Prednisone (Sterapred) 60 mg/m2 PO once per day on days 1 to 5
- Vincristine (Oncovin) 0.4 mg/m2/day IV continuous infusion on days 1 to 4 (total dose per cycle: 1.6 mg/m2)
- Cyclophosphamide (Cytoxan) as follows:
- CD4+ count less than 100/uL: 187 mg/m2 IV over 15 minutes once on day 5
- CD4+ count greater than 100/uL: 375 mg/m2 IV over 15 minutes once on day 5
- In each subsequent cycle, increase dose by 187 mg/m2 if the neutrophil nadir is greater than 500/uL and platelet nadir is greater than 25 x 109/L. Decrease dose by 187 mg/m2 if the neutrophil nadir is less than 500/uL or platelet nadir is less than 25 x 109/L.
- Doxorubicin (Adriamycin) 10 mg/m2/day IV continuous infusion on days 1 to 4 (total dose per cycle: 40 mg/m2)
Supportive medications
- EITHER Filgrastim (Neupogen) 5 mcg/kg SC once per day, starting 24 hours after EPOCH is completed and continuing until "neutrophil recovery"—no absolute count specified
- OR Pegfilgrastim (Neulasta) 6 mg SC once 24 hours after EPOCH is completed
- Trimethoprim/Sulfamethoxazole (Bactrim DS) 160/800 mg PO TIW (e.g. Monday, Wednesday, Friday)
- Fluconazole (Diflucan) 100 mg PO once per day
- Ciprofloxacin (Cipro) 500 mg PO BID, starting on day 8 and to continue to at least day 15 or postnadir ANC of at least 1000
- Other fluoroquinolone can be used at discretion of physician
21-day cycle for 6 to 8 cycles
References
- Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH, Von Roenn J, Dezube BJ, Remick SC, Shah MH, Leichman L, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R; AIDS Malignancy Consortium. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010 Apr 15;115(15):3008-16. Epub 2009 Dec 18. link to original article contains verified protocol link to PMC article PubMed
SC-EPOCH-RR
back to top |
SC-EPOCH-RR: Short Course Rituximab, Etoposide, Prednisone, Oncovin, Cyclophosphamide, Hydroxydaunorubicin, with dose-dense Rituximab
Regimen
Study | Evidence |
Dunleavy et al. 2010 | Phase II |
Dunleavy et al. 2013 | Phase II, <20 pts in this arm |
Dunleavy et al. 2010 reports on HIV+ DLBCL patients, whereas Dunleavy et al. 2013 reports on HIV+ Burkitt lymphoma patients. The regimen is the same.
Chemotherapy
- Rituximab (Rituxan) 375 mg/m2 IV over 3 hours once per day on days 1 & 5
- Etoposide (Vepesid) 50 mg/m2/day IV continuous infusion on days 1 to 4 (total dose per cycle: 200 mg/m2)
- Prednisone (Sterapred) 60 mg/m2 PO once per day on days 1 to 5
- Vincristine (Oncovin) 0.4 mg/m2/day IV continuous infusion on days 1 to 4 (total dose per cycle: 1.6 mg/m2)
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV over 2 hours once on day 5
- Doxorubicin (Adriamycin) 10 mg/m2/day IV continuous infusion on days 1 to 4 (total dose per cycle: 40 mg/m2)
Dose modifications
- Cyclophosphamide (Cytoxan):
- In the subsequent cycle, decrease dose by 187 mg/m2 if ANC was less than 500/uL for 2 to 4 days or platelets were less than 25 x 109/L for 2 to 4 days.
- In the subsequent cycle, decrease dose by 375 mg/m2 if ANC was less than 500/uL for 5 or more days or platelets were less than 25 x 109/L for 5 or more days.
- If dose-reduced in prior cycle, increase dose by 187 mg/m2, up to maximum of 750 mg/m2, if ANC was greater than 500/uL and platelets were greater than 25 x 109/L for the entire cycle.
CNS prophylaxis
- Methotrexate (MTX) 12 mg IT once per day on days 1 & 5 of cycles 3 to 5 (6 total doses)
Supportive medications
- Filgrastim (Neupogen) 300 mcg SC once per day starting on day 6, continue until ANC greater than 5k/uL above nadir
- Trimethoprim/Sulfamethoxazole (Bactrim DS) 160/800 mg PO TIW (e.g. Monday, Wednesday, Friday)
- Omeprazole (Prilosec) 20 mg PO once per day (or equivalent)
- Docusate (Colace) and Sennosides (Senna) 2 tablets PO BID as necessary for constipation
- Lactulose 20 gms PO Q6H as necessary for constipation.
21-day cycles for one cycle beyond CR, minimum 3 and maximum of 6 cycles
References
- Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS, Carrasquillo JA, Steinberg SM, Yarchoan R, Jaffe ES, Wilson WH. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010 Apr 15;115(15):3017-24. Epub 2010 Feb 3. link to original article contains verified protocol link to PMC article PubMed
- Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, Widemann B, Staudt LM, Jaffe ES, Little RF, Wilson WH. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013 Nov 14;369(20):1915-25. link to original article contains verified protocol link to PMC article PubMed
Stanford V
back to top |
Regimen
Study | Evidence |
Spina et al. 2002 | Phase II |
Note: this regimen was for HIV-associated Hodgkin lymphoma, unfavorable stage I or advanced stage.
Chemotherapy
- Doxorubicin (Adriamycin) 25 mg/m2 IV once per week on weeks 1, 3, 5, 7, 9, 11
- Vinblastine (Velban) 6 mg/m2 IV once per week on weeks 1, 3, 5, 7, 9, 11
- Mechlorethamine (Mustargen) 6 mg/m2 IV once per week on weeks 1, 5, 9
- Etoposide (Vepesid) 60 mg/m2 IV once per day for two successive days on weeks 3, 7, 11
- Vincristine (Oncovin) 1.4 mg/m2 (maximum of 2mg in any individual dose) IV once per week on weeks 2, 4, 6, 8, 10, 12
- Bleomycin (Blenoxane) 5 units/m2 IV once per week on weeks 2, 4, 6, 8, 10, 12
- Prednisone (Sterapred) as follows:
- Weeks 1 to 10: 40 mg/m2 PO every other day
- Weeks 11 & 12: taper by 10 mg/m2 every other day until off
Supportive medications
- Filgrastim (Neupogen) 5 mcg/kg SC once per day on days 3 to 7, 9 to 13, 17 to 21, 23 to 26
- Trimethoprim/Sulfamethoxazole (Bactrim DS) (160/800 mg) PO once per day throughout the course of treatment
- Fluconazole (Diflucan) 100 mg PO once per day throughout the course of treatment
12-week course, followed by:
Radiotherapy
- 36 Gy of consolidative radiation (2 Gy in 18 fractions)
References
- Spina M, Gabarre J, Rossi G, Fasan M, Schiantarelli C, Nigra E, Mena M, Antinori A, Ammassari A, Talamini R, Vaccher E, di Gennaro G, Tirelli U. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood. 2002 Sep 15;100(6):1984-8. link to original article contains verified protocol PubMed
Consolidation after salvage therapy
BEAM -> autologous hematopoietic cell transplant
back to top |
BEAM: BiCNU (Carmustine), Etoposide, Ara-C (Cytarabine), Melphalan
Regimen
Study | Evidence |
Alvarnas et al. 2016 (BMT CTN 0803/AMC 071) | Phase II |
Preparative regimen
- Carmustine (BiCNU) 300 mg/m2 IV once on day -6
- Etoposide (Vepesid) 100 mg/m2 IV Q12H on days -5 to -2 (8 total doses)
- Cytarabine (Cytosar) 100 mg/m2 IV Q12H on days -5 to -2 (8 total doses)
- Melphalan (Alkeran) 140 mg/m2 IV once on day -1
Hematopoietic cells are re-infused on day 0
References
- Re A, Cattaneo C, Michieli M, Casari S, Spina M, Rupolo M, Allione B, Nosari A, Schiantarelli C, Vigano M, Izzi I, Ferremi P, Lanfranchi A, Mazzuccato M, Carosi G, Tirelli U, Rossi G. High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol. 2003 Dec 1;21(23):4423-7. Epub 2003 Oct 27. Erratum in: J Clin Oncol. 2004 Jan 15;22(2):386. Mazzuccato Maurizio [corrected to Mazzuccato Mauro]. link to original article PubMed
- Alvarnas JC, Le Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, Devine S, Baiocchi R, Lozanski G, Kaplan L, Noy A, Popat U, Hsu J, Morris LE Jr, Thompson J, Horowitz MM, Mendizabal A, Levine A, Krishnan A, Forman SJ, Navarro WH, Ambinder R. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. Blood. 2016 Aug 25;128(8):1050-8. Epub 2016 Jun 13. link to original article contains verified protocol link to PMC article PubMed